HTA must consider health equity for progress

By HEOR Staff Writer

March 24, 2023

ICER has released a White Paper on Health Equity. This paper measures the impact of health technology assessment (HTA) on equity, and suggests approaches to leverage HTA to advance health equity for racial, ethnic, and socially disadvantaged groups.

When decision-makers evaluate data to inform pricing and insurance coverage, they must consider the implications for health equity. They have taken a close look at every step of our work to assess if we and other HTA groups can make improvements and will enhance the discussion on clinical trial diversity.

It is essential for HTA bodies to be aware of how to add equity into the methods of health technology assessment, and if that can be accomplished by utilizing innovative methods that are expansions of traditional cost-effectiveness analyses, through evidence-grounded deliberative approaches, or a combination of the two.

Reference url

Recent Posts

Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...
Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promising New Data
Johnson & Johnson has announced promising new data across multiple solid tumor types, which will be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, and the company describes this as "a new era" in their solid tumor research. The press release highlights ...